Parkinson's biomarker work is converging on the alpha-synuclein seed-amplification assay

Reading the signal

The alpha-synuclein seed-amplification assay (alpha-syn-SAA, also known as RT-QuIC for alpha-synuclein) is a CSF-based assay that detects misfolded alpha-synuclein seeds. The assay amplifies the seeded misfolding reaction in vitro, providing a sensitive readout of pathological alpha-synuclein aggregation.

The performance data:

• In established Parkinson's disease, sensitivity is in the high 80s to low 90s percent and specificity is in the high 90s
• In dementia with Lewy bodies, similar sensitivity and specificity
• In REM sleep behaviour disorder (a known prodromal state for synucleinopathy), the assay is positive in the substantial majority of clinically defined cases, supporting its use in prodromal identification
• In multiple system atrophy, the assay performs differently because the alpha-synuclein conformation in MSA is distinct from PD/DLB; the assay can be configured to differentiate

The assay is now being used in research-grade and increasingly in clinical-research settings. Routine clinical use is more constrained because CSF sampling has practical barriers and because the field has not fully converged on use cases beyond research.

Plasma-based alpha-synuclein assays are in development; the analytical performance is improving but is not yet at the level of CSF.

Commercial implications

For sponsors of Parkinson's pipeline (disease-modifying therapy, symptomatic therapy):

1. Trial enrolment can move toward biomarker-confirmed populations. Clinically diagnosed Parkinson's disease has historically had a substantial misdiagnosis rate (10 to 20 percent in studies). Biomarker-confirmed enrolment improves trial-population homogeneity and statistical power
2. The prodromal opportunity is the strategic upside. Disease-modifying therapy in prodromal synucleinopathy is more likely to deliver clinical benefit than treatment of established disease, and the alpha-syn-SAA enables prodromal identification at the population scale
3. The diagnostic-pathway commercial relationship matters. As the assay moves toward routine clinical use, the lab-side pathway and the specialist-centre access for CSF sampling become commercial inputs

What we are watching

• Plasma-based alpha-synuclein assay validation as it progresses toward routine clinical use
• Pivotal trial designs for disease-modifying Parkinson's therapy that incorporate alpha-syn-SAA enrolment
• Reimbursement pathways for the alpha-syn-SAA in research-grade and routine clinical use